SCHEMBL2461910

SCHEMBL2461910

CNC(=O)c1ccc(-c2ccc([C@@](C)(F)CNS(=O)(=O)C(C)C)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 9/20 0.44
PLK1 P53350 1/20 0.40
EPHX2 P34913 2/20 0.39
NR1H4 Q96RI1 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
HDAC4 P56524 1/20 0.39
CA2 P00918 1/20 0.38
PDK2 Q15119 1/20 0.38
RORC P51449 1/20 0.37
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
PPARA Q07869 1/20 0.36
GRIA2 P42262 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14394695 1.00 GRIA4 (0.44) GRIA4PLK1EPHX2NR1H4HDAC6
SCHEMBL2143206 1.00 GRIA4 (0.44) GRIA4PLK1EPHX2NR1H4HDAC6
SCHEMBL5186058 0.89 GRIA4 (0.57) GRIA4EPHX2NR1H4
SCHEMBL3711628 0.88 GRIA4 (0.48) GRIA4CA2GRIA2CA1
SCHEMBL13255710 0.88 GRIA4 (0.48) GRIA4CA2GRIA2CA1
SCHEMBL5187397 0.88 HDAC4 (0.43) GRIA4EPHX2NR1H4HDAC6HDAC4
SCHEMBL5186190 0.88 GRIA4 (0.44) GRIA4EPHX2NR1H4CA2RORC
SCHEMBL5187928 0.85 GRIA4 (0.43) GRIA4EPHX2NR1H4HDAC4PDK2
SCHEMBL8294927 0.84 GRIA4 (0.41) GRIA4EPHX2NR1H4GRIA2
SCHEMBL6561639 0.84 GRIA4 (0.51) GRIA4EPHX2NR1H4CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006034196-A1 COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR LIFELIKE BIOMATIC INC. (US) 2006-03-30 WO claimed
US-20060063707-A1 Compositions for enhancing memory and methods therefor LIFELIKE BIOMATIC, INC. (US) 2006-03-23 US claimed
US-12064410-B2 Compositions and methods for stimulating ventilatory and/or respiratory CASE WESTERN RESERVE UNIVERSITY (US) 2024-08-20 US disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
US-20230142111-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-11 US disclosed
US-20160257957-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-09-08 US disclosed
EP-2544688-B1 METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME HARVARD COLLEGE (US) 2016-09-07 EP disclosed
US-20130058915-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS Children's Medica Center Corporation (US) 2013-03-07 US disclosed
EP-2544688-A2 METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS President and Fellows of Harvard College (US) 2013-01-16 EP disclosed
WO-2011109398-A2 METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-09-09 WO disclosed
US-20100069377-A1 TREATMENT OF FEMALE SEXUAL DYSFUNCTION BY COMPOUNDS THAT POSITIVELY MODULATE AMPA-TYPE GLUTAMATE RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-03-18 US disclosed
WO-2008118644-A1 TREATMENT OF FEMALE SEXUAL DYSFUNCTION BY COMPOUNDS THAT POSITIVELY MODULATE AMPA-TYPE GLUTAMATE RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-10-02 WO disclosed
WO-2006034196-A1 COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR LIFELIKE BIOMATIC INC. (US) 2006-03-30 WO disclosed
US-20060063707-A1 Compositions for enhancing memory and methods therefor LIFELIKE BIOMATIC, INC. (US) 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063707-A1 Compositions for enhancing memory and methods therefor GRIN1, GRIN3A, GRIN2A GRIA4 19/4885PLK1 1493/4885EPHX2 3478/4885
US-12064410-B2 Compositions and methods for stimulating ventilatory and/or respiratory CTH, SLC25A20, CRH GRIA4 422/4885PLK1 3590/4885EPHX2 1632/4885
US-20230142111-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS GRIN2D, GRIN2A, GRIN2C GRIA4 14/4885PLK1 1060/4885EPHX2 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.